Main menu
You are here
A Natural and Pragmatic Experiment Evaluating the Impact of Delaying or Withholding Antiviral Therapy for Early-Stage Chronic Hepatitis C
Because current treatment for hepatitis C is so effective but expensive, an important question for caregivers and society is whether withholding treatment from patients with low-stage liver fibrosis, as is done by some insurers but not others, is justifiable. Our proposal is to rely on an observational population study design that exploits variation in insurance coverage for treating early-stage hepatitis C.
Other Information:
- Principal Investigator: Jules Dienstag, MD; Massachusetts General Hospital
- Status: Application withdrawn due to restructuring of CMS data available
- PCORI Trial Website